Cancer Immunotherapy News and Research

RSS

Cancer immunotherapy does not interfere with COVID-19 immunity in vaccinated patients, study shows

Research findings published in Frontiers in Immunology show that cancer immunotherapy does not interfere with COVID-19 immunity in previously vaccinated patients.

31 Jan 2023

Researchers identify an unexpected driver of cancer immunotherapy resistance

A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has identified an unexpected driver of cancer immunotherapy resistance: the harmful effect of chronic Type I Interferon signaling on tumor-killing CD8+ T cells.

27 Jan 2023

Persistent tumor mutation burden linked with therapeutic response to immunotherapy

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

26 Jan 2023

Researchers develop innovative STAb therapy for a type of leukemia

Researchers of the Hospital Universitario 12 de Octubre in Madrid and the Josep Carreras Leukaemia Research Institute have developed a cell therapy for a type of leukemia which currently has very few treatment options.

16 Jan 2023

Silencing the immune evasion gene enhances cancer cells' susceptibility to immunotherapy

Immune checkpoint inhibitors are important medications that boost the immune system's response against various cancers, but some patients' cancer cells are unaffected by the drugs or develop resistance during treatment.

12 Jan 2023

Simple method increases the efficacy of T cell therapy by cytokine conjugation

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.

11 Jan 2023

Study details the “immunometabolic editing” mechanism of tumor evolution

A Ludwig Cancer Research study has discovered that the immune system's surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.

5 Jan 2023

Extracellular vesicles enhance cancer immunotherapy

Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumors sensitive to a type of immunotherapy drug called a checkpoint inhibitor.

22 Dec 2022

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Scientists at UC San Francisco have engineered T cells to produce a potent anti-cancer cytokine, but only when they encounter tumor cells.

16 Dec 2022

Using synthetic gene circuits to better control the timing of immunotherapy

In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.

16 Dec 2022

Study provides novel therapeutic targets for enhancing the antitumor immunity of γδ-T cells in diabetes

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that high glucose impairs the antitumor activity of immune effector γδ-T cells, which contributes to the increased cancer risk in diabetes and that metabolic reprogramming by glucose control may improve the antitumor activity of γδ-T cells.

30 Nov 2022

Review: Phenotypes and origins of myeloid-derived suppressor cells

A new review was published in Oncotarget's Volume 13 on November 17, 2022, entitled, "Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more."

30 Nov 2022

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

Augmented drug preferentially eliminates cancer cells but does not harm healthy cells

Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a "prodrug" -; a medicine designed to release its payload in a particular area of the body and in no other areas.

17 Nov 2022

Machine learning algorithm predicts a tumor’s response to immune checkpoint blockade

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades.

16 Nov 2022

Study finds no differences in CAR T-cell therapy outcomes among pediatric ALL patients across different socioeconomic levels

Social determinants of health affect the outcomes of many illnesses, and pediatric cancer is no exception. In fact, children with acute lymphoblastic leukemia (ALL) living in poverty are significantly more likely to relapse and die from their disease than those from wealthier backgrounds.

11 Nov 2022

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy.

10 Nov 2022

Focused ultrasound treatment offers long-term relief for patients with essential tremor

A scalpel-free, high-tech form of brain surgery pioneered at UVA Health offers long-term relief for patients with essential tremor, a common movement disorder, a five-year review shows.

10 Nov 2022

New nanovaccine greatly improves cytokine production

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer. However, immune checkpoint inhibition therapy is only effective in 20%–30% of cancer patients, so developing better drug delivery systems to induce anticancer cellular immunity is necessary.

1 Nov 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022